New telehealth clinic to provide VR-powered treatment

XRHealth has announced the launch of a new telehealth clinic that allows patients to receive care at home via virtual reality (VR) technology.

The clinic, scheduled to open on March 1, features healthcare providers certified in Massachusetts, Connecticut, Florida, Michigan, Delaware, California, New York, North Carolina and Washington D.C. Certification in additional states is expected “in the coming months.”

Treatment for traumatic brain injuries and stroke rehabilitation, stress and anxiety, chronic pain, hot flashes, neurological disorders and more will be available at the clinic. Services will be covered by Medicare “and most major insurance providers.”

When patients first seek treatment from XRHealth’s clinic, they undergo an initial assessment and are sent a VR headset if necessary. They are then trained on the technology as needed, and the healthcare providers are able to view what the patient is “seeing” at all times.

“XRHealth is modernizing and revolutionizing the way healthcare is operating today,” Eran Orr, CEO of XRHealth, said in a prepared statement. “We are utilizing the most advanced forms of technology like virtual reality to provide patients with optimal care in the comfort of their own homes while providing top-notch clinicians with ongoing status of their progress. Patients can now ‘go’ to a virtual clinic without the need to leave their homes at all.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.